Evidence map›Paper›PMID 37298322›Full record

ArticleInternational journal of molecular sciences2023

Elucidating the Therapeutic Potential of Bis(Maltolato)OxoVanadium(IV): The Protective Role of Copper in Cellular Metabolism.

Lorenzo Rivas-García, Alfonso López-Varela, José L Quiles, María Montes-Bayón, Pilar Aranda, Juan Llopis, Cristina Sánchez-González

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lorenzo Rivas-GarcíaDepartment of Physiology, Institute of Nutrition and Food Technology "José Mataix Verdú", Biomedical Research Centre, University of Granada, 18016 Armilla, Spain.ORCID 0000-0002-0413-8432
Alfonso López-VarelaDepartment of Physiology, Institute of Nutrition and Food Technology "José Mataix Verdú", Biomedical Research Centre, University of Granada, 18016 Armilla, Spain.ORCID 0000-0002-0504-5086
José L QuilesDepartment of Physiology, Institute of Nutrition and Food Technology "José Mataix Verdú", Biomedical Research Centre, University of Granada, 18016 Armilla, Spain.ORCID 0000-0002-9048-9086
María Montes-BayónInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Department of Physical and Analytical Chemistry, Faculty of Chemistry, University of Oviedo, C/ Julián Clavería 8, 33006 Oviedo, Spain.ORCID 0000-0001-6114-9405
Pilar ArandaDepartment of Physiology, Institute of Nutrition and Food Technology "José Mataix Verdú", Biomedical Research Centre, University of Granada, 18016 Armilla, Spain.ORCID 0000-0002-7982-1359
Juan LlopisDepartment of Physiology, Institute of Nutrition and Food Technology "José Mataix Verdú", Biomedical Research Centre, University of Granada, 18016 Armilla, Spain.ORCID 0000-0001-6803-2584
Cristina Sánchez-GonzálezDepartment of Physiology, Institute of Nutrition and Food Technology "José Mataix Verdú", Biomedical Research Centre, University of Granada, 18016 Armilla, Spain.ORCID 0000-0002-1044-4858
Universidad de Granada · ESUniversidad de Oviedo · ES

Funding

Ministry of Economy, Industry and Competitiveness SAF2011-29648Regional Government of Andalusia Project P06-CTS-01435
6 · The paper itself

Abstract

Vanadium (V) is a trace mineral whose biological activity, role as a micronutrient, and pharmacotherapeutic applications remain unknown. Over the last years, interest in V has increased due to its potential use as an antidiabetic agent mediated by its ability to improve glycemic metabolism. However, some toxicological aspects limit its potential therapeutic application. The present study aims to evaluate the effect of the co-treatment with copper (Cu) and bis(maltolato)oxovanadium(IV) (BMOV) as a possible strategy to reduce the toxicity of BMOV. Treating hepatic cells with BMOV reduced cell viability under the present conditions, but cell viability was corrected when cells were co-incubated with BMOV and Cu. Additionally, the effect of these two minerals on nuclear and mitochondrial DNA was evaluated. Co-treatment with both metals reduced the nuclear damage caused by BMOV. Moreover, treatment with these two metals simultaneously tended to reduce the ND1/ND4 deletion of the mitochondrial DNA produced with the treatment using BMOV alone. In conclusion, these results showed that combining Cu and V could effectively reduce the toxicity associated with V and enhance its potential therapeutic applications.

Indexed as

CopperTrace ElementsDNA, MitochondrialHypoglycemic AgentsPyronesVanadatesVanadiumbis(maltolato)oxovanadium(IV)CopperDNA, MitochondrialHypoglycemic AgentsPyronesTrace ElementsVanadatesVanadiumcopperDNAmineralmitochondrianutritionvanadium

Identifiers

PMID37298322
PMCPMC10253854
OpenAlexW4378575179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.